INCUBETA
Lars Lehne has been appointed Group CEO of Incubeta , the independent digital marketing services group. The former SYZYGY AG CEO will be taking over from the founder Alan Lipschitz, whose company Interface made the reverse acquisition of IncuBeta Holdings in 2011. Alan will be moving into the role of Chairperson of the Board of Directors of Incubeta.
Lars brings with him more than 30 years of industry experience. Prior to Incubeta Lars spent four years as Global CEO at SYZYGY, a publicly listed WPP company. Before that, he spent seven years at Google as Country Director Agency DACH, paving the way for the tech giant quadrupling revenues in Germany. He has also held various senior management positions in agencies including Maxus, GroupM, Carat and MEC.
In addition to his current role as new Group CEO of Incubeta, Lars is a member of the advisory board of Yext, and betterplace.org, a Berlin based NGO. He’s also an Angel Investor in CLAIMINI GmbH. As Group CEO, Lars will be leading company positioning and growth, including its operations in North America, driving the business strategy and further uniting the group across the globe.
Incubeta operates across 14 countries with offices in cities including London, New York, Los Angeles, Madrid, Sydney and Cape Town. In 2013 the highly successful Net Media Planet (NMPi) was acquired, which established significant growth for Incubeta as it boosted its advertising offerings. The subsequent acquisition in 2016 of forward-thinking marketing technology specialist DQ&A, extended the company’s geographical and product growth. This was followed by the acquisition of market leading creative specialist, Joystick, in 2018. Through these acquisitions, Incubeta offers clients a full suite of unrivalled services connecting Media, Technology and Creative.
In the last twelve months, Incubeta has launched several new innovative platforms. This has included the award-winning proprietary Seamless technology, including Seamless Search – which measures the incrementality of paid and organic SEO keywords – and Seamless Creative – which unifies media activity and creative assembly at scale. The company has also made a series of new appointments including senior hire John Cawdery as US CEO.
Alan Lipschitz, Founder and Chairperson of the Board, comments: “Having started a small South African business many years ago, I am so very proud of how far the company has come. By building a fantastic team around me and adding inspirational businesses from around the world, Incubeta has grown into a leading player in digital marketing services. The company is in a great place, yet I believe in order to accelerate pace and to meet the challenges of the future we need a different type of leader.
“I have the utmost faith Lars is the leader the company needs to take Incubeta forward. He has the expertise to bring the team further together, drive clear strategy, and build on the fantastic foundation I have been able to create with my wonderful team. So it is with great pride and pleasure that I hand the mantle of Chief Executive Officer of the Incubeta Group to Lars Lehne.”
Lars Lehne, Group CEO of Incubeta, comments: “I’m thrilled and honoured to be joining such a forward-thinking and innovative company. Incubeta has continued to grow during one of the most challenging years for the industry which is a testament to the quality and hard work of every team member across the globe. The company has flourished under Alan’s leadership and it's a great privilege that he’s trusting me to take his dream forward.
“As marketing continues to evolve at a rapid pace, it’s harder now than ever before for brands to connect with their customers. By integrating Media, Technology, and Creative in a seamless way Incubeta has developed the right services and products to help clients grow in a digital world. Incubeta puts the ownership of the customer experience back into the hands of its clients. I can’t wait to see what the next chapter for Incubeta looks like.”
-ENDS-
About Incubeta:
Incubeta is the union of three market leading specialists in Technology, Media, and Creative – DQ&A, NMPi, and Joystick respectively. By seamlessly integrating these three specialisms and rethinking the rules of marketing, Incubeta puts the ownership and control of the customer experience back in the hands of the advertiser, both brands and agencies.
As the largest and longest established GMP sales partner in EMEA and APAC, Incubeta has proven through working with top-tier brands that they are leading specialists in helping advertisers tackle complex projects such as in-housing, dynamic creative, data integration, real 1:1 marketing, and industry-specific segmentation modeling. Incubeta is primed to help advertisers deliver complex use cases across Google's Maturity Framework and Menu of Services.
Find out more at: incubeta.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210113005451/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom